CoChat

Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)

Open access
Iwata, Hiroji, Inoue, Kenichi, Kaneko, Koji, Ito, Yoshinori, Tsugawa, Koichiro, Hasegawa, Ayumi, Nakagawa, Shintaro, Kuratomi, Hiroyasu, Tamura, Kenji · 2019 · Japanese Journal of Clinical Oncology

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

BACKGROUND: In the randomised Phase 3 IMpassion130 trial, atezolizumab combined with nab-paclitaxel (atezo + nab-P) in 902 patients with triple-negative breast cancer (TNBC) showed prolonged progression-free survival (PFS) in both the intention-to-treat (ITT) population and programmed death-ligand 1 (PD-L1)-positive subgroup compared with placebo plus nab-P (plac + nab-P). This study assessed the efficacy and safety of atezo + nab-P in the IMpassion130 Japanese subpopulation. METHODS: Eligible patients had unresectable locally advanced or metastatic TNBC previously untreated with chemotherapy for metastatic disease. Patients were randomised 1:1 to receive either atezo + nab-P or plac + nab-P. Co-primary endpoints were investigator-assessed PFS and overall survival (ITT population and PD-L1-positive subgroup). These were also assessed in the Japanese subpopulation. RESULTS: There were 65 Japanese patients (34 atezo + nab-P; 31 plac + nab-P). The PD-L1-positive subgroup included 25 patients (12 atezo + nab-P; 13 plac + nab-P). Median PFS was 7.4 months (atezo + nab-P) versus 4.6 months (plac + nab-P; hazard ratio [HR], 0.47; 95% CI, 0.25-0.90). In the PD-L1-positive subgroup, median PFS was 10.8 months (atezo + nab-P) versus 3.8 months (plac + nab-P; HR, 0.04; 95% CI, <0.01-0.35). Safety results in the Japanese subgroup were consistent with those in the overall population. The Japanese subgroup had a lower incidence of adverse events leading to treatment withdrawal than the overall population. More patients in the atezo + nab-P arm had neutrophil count decreases and stomatitis than patients in the plac + nab-P arm. CONCLUSIONS: Atezo + nab-P efficacy in Japanese patients was consistent with the overall IMpassion130 population. No new safety signals were observed, and tolerability was consistent with that of the overall population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jjco/hyz135

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. (A) Investigator-assessed progression-free survival in Japanese patients (ITT) and (B) PD-L1–positive patients. Atezo, atezolizumab; ITT, intention-to-treat; nab-Pac, nab-paclitaxel; NE, not estimable; PD-L1, programmed death-ligand 1.
Figure 1. (A) Investigator-assessed progression-free survival in Japanese patients (ITT) and (B) PD-L1–positive patients. Atezo, atezolizumab; ITT, intention-to-treat; nab-Pac, nab-paclitaxel; NE, not estimable; PD-L1, programmed death-ligand 1.CC BY-NC · PubMed Central
Figure 2. (A) Overall survival in Japanese patients (ITT) and (B) PD-L1–positive patients. Atezo, atezolizumab.
Figure 2. (A) Overall survival in Japanese patients (ITT) and (B) PD-L1–positive patients. Atezo, atezolizumab.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 1

  1. National Comprehensive Cancer Network, 2019, NCCN clinical practice guidelines in oncology, Breast Cancer, V1

Cited by

See all 46

Metadata

Authors
Iwata, H., Inoue, K., Kaneko, K., Ito, Y., Tsugawa, K., Hasegawa, A., Nakagawa, S., Kuratomi, H., & Tamura, K.
Affiliations
  • Aichi Cancer Center (JP)
  • Saitama Cancer Center (JP)
  • Niigata Cancer Center Hospital (JP)
  • The Cancer Institute Hospital (JP)
  • St. Marianna University School of Medicine (JP)
  • Chugai Pharmaceutical Co., Ltd. (Japan) (JP)
  • National Cancer Center Hospital (JP)
Corresponding author
Iwata, Hiroji
Venue
Japanese Journal of Clinical Oncology
Published
2019-10-15
Volume
49
Issue
12
Pages
1083-1091
ISSN
  • 0368-2811 (ISSN-L)
  • 1465-3621
OpenAlex
W2980868069
Cited by
46
References
33
Citations by year
2026: 3 · 2025: 5 · 2024: 6 · 2023: 7 · 2022: 9 · 2021: 11 · 2020: 4
FWCI
2.50
Type
journal article
Language
en
Open access
Locations
  • Japanese Journal of Clinical Oncology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Chugai Pharmaceutical
  • F. Hoffmann-La Roche/Genentech/Chugai
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords
atezolizumab, triple-negative breast cancer, Japanese patients, nab-paclitaxel, progression-free survival, overall survival, immune checkpoint inhibitors, treatment safety, neutropenia, stomatitis
MeSH terms
Progression-Free Survival, Adult, Aged, Aged, 80 and over, Albumins, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Japan, Middle Aged, Safety, Paclitaxel, B7-H1 Antigen, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). https://app.cochat.ai/papers/10.1093/jjco/hyz135
The paper
Iwata, H., Inoue, K., Kaneko, K., Ito, Y., Tsugawa, K., Hasegawa, A., Nakagawa, S., Kuratomi, H., & Tamura, K. (2019). Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyz135

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.